Malaria vaccine plus seasonal prevention for children
Part of Infections clinical trials.
This trial tests if adding a malaria vaccine to seasonal preventive medicines helps protect young children better from malaria. It is for healthy children living in certain areas of Burkina Faso and Mali.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child must be between 3 and 59 months old (check age guidelines for your specific group).
- Child must live in the catchment area of a trial health center in Burkina Faso or Mali.
- A parent or guardian must agree in writing to follow study procedures.
- Child must not have a history of severe allergic reactions to any vaccine component.
- Child must not have a known chronic illness or other health problem that would make the study unsafe.
- Child must not have already received another malaria vaccine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a malaria vaccine (PvRII/Matrix-M) and how well it trains the immune system, then follows safety and effectiveness after a controlled malaria exposure. If you qualify, you’ll be monitored closely in the hospital and receive a curative antimalarial treatment after the exposure.
This trial tests a seasonal vaccination schedule with the R21 malaria vaccine to help eliminate malaria in your community. It may be a good fit if you are looking for a way to protect yourself or your child from malaria during peak transmission seasons.
This trial tests a new combination of experimental malaria vaccines to see if they are safe and help protect against malaria. It includes both adults and young children in malaria-affected areas.
This Phase 1/2 study tests a new vaccine meant to protect young children against malaria. If you qualify, your baby would get the study vaccine and be followed for about 12 months to check safety and early signs of protection.
This study looks at how well the R21/Matrix-M malaria vaccine works in real-life settings for children under 5. If your child is eligible for the vaccine and has a fever, they may be able to join and help us understand the vaccine's impact.
This study tests a new malaria vaccine called PfSPZ-LARC2 in healthy adults living in Burkina Faso. If you qualify, the vaccine is given to see if it can protect you from malaria.
Hear when a new Malaria Vaccine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.